Clinical trials: HHT, open to volunteers
Telangiectasia, Hereditary Hemorrhagic
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
This study will examine genes involved in the vascular dysplasia Hereditary haemorrhagic telangiectasia i(HHT)
- Trial name
- NCT00230620
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Imperial College London
Newly Diagnosed Acute Myeloid Leukemia With High Risk
HVA vs IA/DA or VA in the Treatment of ND HR-AML
The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed…
- Trial name
- NCT06810791
- Testing
- HVA, VA, Standard Chemotherapy
- Where
- China
- Volunteers
- 876 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hereditary Hemorrhagic Telangiectasia (HHT)
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
The primary purpose of this study is to assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT).
- Trial name
- NCT07863609
- Testing
- TX002100
- Volunteers
- 20 people
- Sponsor
- Tectonic Operating Company, Inc.
Acute Myeloid Leukemia
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
This study is a single-center, single-arm, prospective phase II clinical trial evaluating the efficacy and safety of the VAH (Venetoclax and Azacitidine combined with Homoharringtonine) regimen, followed by allo-HSCT for…
- Trial name
- NCT06483906
- Testing
- Venetoclax, Azacitidine and Homoharringtonine
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hereditary Hemorrhagic Telangiectasia
Body Donation in HHT
The possibility of body donation in hereditary hemorrhagic telangiectasia (HHT) means that human tissue samples with and without vascular malformations can be analyzed. The aim is to gain insights into the disease mechanism.
- Trial name
- NCT07826845
- Testing
- body donation in HHT
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with…
- Trial name
- NCT07743671
- Testing
- Engasertib
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vaderis Therapeutics AG
Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in China and worldwide. Although standard immunochemotherapy with Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine…
- Conditions
- Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
- Trial name
- NCT07159906
- Testing
- Homoharringtonine, BCL-2 inhibitor, CD20 Antibody
- Where
- China
- Volunteers
- 62 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Bevacizimab, HHT
Bevacizumab in the Treatment of HHT
Clinical Study Abstract (Ethics Application) Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant vascular disorder characterized by recurrent intractable epistaxis and multi-organ arteriovenous malformations.
- Trial name
- NCT07828015
- Testing
- Bevacizumab, nasal electrocoagulation., Thalidomide (50mg)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Vascular Anomaly, Osler Rendu Disease
Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study
There are no prospective studies of pregnancies for the diseases studied here in (Heredity Hemorrhagic Telangiectasia, Marfan syndrome or related, primary lower limb lymphedema, superficial arteriovenous malformations, and…
- Conditions
- Vascular Anomaly, Osler Rendu Disease, Marfan Syndrome or Related, Lymphedema Primary
- Trial name
- COGRare5 (NCT04194619)
- Testing
- Questionnaire
- Where
- 37 sites in France
- Volunteers
- 400 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia
Cardiac Evaluation in Hereditary Hemorrhagic Telangiectasia
Hereditary haemorrhagic telangiectasia (HHT) is a rare autosomal dominant genetic disease associated with mutations in genes encoding proteins of the transforming growth factor β (TGF-β) family, i.e.
- Trial name
- CARDI-HHT (NCT07101575)
- Testing
- Transthoracic echocardiography
- Volunteers
- 380 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Acute Myeloid Leukemia (AML)
Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients
This is a multi-center, prospective, single-arm, phase 2 clinical study conducted in China to evaluate the efficacy and safety of Lisafotoclax combined with Decitabine and Homoharringtonine in patients with acute myeloid leukemia…
- Trial name
- NCT07505160
- Testing
- Lisafotoclax, Decitabine, Homoharringtonine
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis
- Trial name
- CHORUS (NCT06259292)
- Where
- 16 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Cure HHT
Hereditary Hemorrhagic Telangiectasia
Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia
Patients with hereditary hemorrhagic telangiectasia (HHT) suffer from an inherited disorder leading to systemic vascular malformations.
- Trial name
- NCT04469517
- Testing
- hypoxic induced factors
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Prostate Cancer
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
The project aims to verify the therapeutic effect of neoadjuvant homoharringtonine combined with androgen deprivation therapy in patients with localized high-risk/very high-risk, regional lymph node-metastatic, or metastatic…
- Trial name
- NCT07163910
- Testing
- homoharringtonine, Radical prostatectomy
- Where
- China
- Volunteers
- 93 people
- Sponsor
- baotai Liang
Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.
- Trial name
- NCT04501120
- Testing
- Lisaftoclax (APG-2575), Reduced-dose HHT, standard-dose HHT
- Where
- 12 sites in China
- Volunteers
- 682 people
- Sponsor
- Ascentage Pharma Group Inc.
Hereditary Haemorrhagic Telangiectasia (HHT)
Quality of Life in Pediatric Participants With HHT
This observational study evaluates health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-25 years with Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- NCT07474428
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Ashley Nelson
Hereditary Hemorrhagic Telangiectasia
Quality of Life in Patients With Hemorrhagic Telangiectasia
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler's disease, is a genetic disorder that leads to abnormal blood vessel formations.
- Trial name
- NCT06261333
- Testing
- Questionnaires
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- University Hospital, Essen
AML (Acute Myeloid Leukemia)
Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML
This study aims to explore a superior first-line induction remission regimen by incorporating Chidamide into the modified VAH chemotherapy combined with targeted therapy regimen, leveraging its dual epigenetic modulation…
- Trial name
- NCT07643636
- Testing
- Chidamide (Chi)+VAH
- Volunteers
- 46 people
- Sponsor
- Dongguan People's Hospital
Telangiectasia, Hereditary Hemorrhagic
Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
This observational study is for individuals with Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations that are reviewed at the Hammersmith Hospital, London.
- Trial name
- NCT00230685
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Imperial College London
Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Pediatric T-cell ALL Protocol
This is a prospective, multicenter study conducted within the Chinese Children's Cancer Group (CCCG). The study aims to evaluate whether the addition of three novel agents, dasatinib, venetoclax and homoharringtonine, can improve…
- Conditions
- Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Trial name
- CCCG-TALL-2025 (NCT06855810)
- Testing
- Venetoclax, Dasatinib, homoharringtonine
- Where
- 27 sites in China, Hong Kong
- Volunteers
- 610 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China